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Background
The combination of IFN-alpha and ribavirin is an
approved treatment for chronic hepatitis C virus (HCV)
infection.  IFN-alpha is given in a dose of 3 million units
subcutaneously three times a week for a period of six
months for genotypes 2 and 3 and one year for genotypes 1
and 4.1 A sustained response to interferon therapy however
remains a difficult goal to achieve in hepatitis C patients.
Current evidence suggests that only up to 15-20% of
patients demonstrate a sustained response to interferon
monotherapy. Combination treatment with interferon and
Ribavirin increases the sustained response rate to about
40%.2-4 Therefore, therapy of chronic hepatitis C with INF-
alpha and ribavirin is still less than ideal. This combination
does not influence much the initial response rates so that the
problem of the non-responding patients to interferon
remains. Most non-responders are infected with genotype 1.
A recent meta-analysis demonstrated a sustained virological
response of only 13-14% with interferon plus ribavirin in
non-responders to interferon monotherapy.5,6 In patients
who have failed to respond to interferon plus ribavirin, there
are no clear data to indicate that re-treatment will be bene-
ficial.
Patients who relapse after an initial response to
interferon may respond to a combination of interferon with
ribavirin.7 However, not all relapsers respond to retreat-
ment. Moreover, a different strategy may be needed for
patients who are considered as non-responders to interferon
therapy. Because of the limitations of antiviral drugs, other
ways to enhance the immune system's ability to clear HCV
should be explored.
Thymosin alpha 1, a 28-amino acid peptide origi-
nally derived from the thymus gland, has been sequenced
and chemically synthesized.8,9 It has been evaluated for its
immunomodulatory activities and therapeutic potential in
several diseases, including chronic hepatitis B and C. The
basis for its effectiveness may be its capacity to modulate
immunological responsiveness and to increase T cell differ-
entiation and maturation.8 For example thymosin increases
CD3 +, CD4 + and CD8 + cell proliferation and also stimu-
lates NK cell activity. Initial trials with thymosin monother-
apy for chronic hepatitis C showed mixed results. However,
combination therapy have had different results as thymosin
has been suggested to add to interferon in chronic hepatitis
C patients. The aim of the present study was to evaluate the
efficacy and safety of a triple regimen, a combination treat-
ment with thymosin alpha  1 and interferon alfa with rib-
avirin in patients who have not previously responded or
relapsed after treatment with interferon in combination with
ribavirin.
Patients and Methods
In this open labeled study two categories of patients
were included. (1) Non-responders: patients previously
treated with interferon in combination with ribavirin for at
least three months in case of genotype 3 infection and six
months for genotype 1, and had not shown a response by
normalization of their ALT levels and disappearance of
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HCV RNA from serum. (2) Relapsers: patients who
were HCV RNA negative at the end of the treatment with
interferon and ribavirin combination but relapsed at six
months post-treatment. Patients in both groups must not
have received interferon alpha, ribavirin or other
immunomodulatory drugs such as corticosteroids within 3
months of entering this trial. Other exclusion criteria were
co-infection with either human immunodeficiency virus
(HIV) or hepatitis B virus (HBV), decompensated liver dis-
ease as indicated by any of the following; serum bilirubin
>2 x upper limit of normal, prothrombin time >4 seconds
prolonged, serum albumin <3.5 g/dL, history of ascites,
variceal hemorrhage or hepatic encephalopathy, evidence of
bone marrow suppression as indicated by hemoglobin <10
gm/dL, white blood cell count <4xl09/L, platelet count
<100x109/L, serum creatinine >1.5 times upper limit of nor-
mal, serious concurrent medical illnesses such as uncon-
trolled diabetes and  tuberculosis, history of serious adverse
effects with previous interferon therapy, pregnant or breast
feeding mothers, concomitant chronic use of aspirin, non-
steroidal anti-inflammatory drugs, immunosuppressive
drugs or concomitant chronic use of any drug known to be
hepatotoxic.
Written, informed consent was obtained from
patients fulfilling the eligibility criteria. Medical history
was taken and physical examination including height and
weight was performed. Quantitative serum HCV RNA was
determined by bDNA assay version 2.0 (Chiron,
Emeryville, CA). Once patients became negative with the
above assay, reverse transcription polymerase chain reac-
tion assay (The AMPLICOR HCV Test, v2.0, Roche) with
a sensitivity of 50 IU/ml was used in the follow up visits.
HCV genotype was determined by the Murex HCV serotyp-
ing 1-6 assays (Murex Biotech, UK). A liver biopsy was
obtained prior to therapy. Hepatic inflammation and fibrosis
were assed by the METAVIR scoring system.10 The fibrosis
stage was assessed on a scale of 0-4 and activity was grad-
ed on a scale of 0-3. Abdominal ultrasound scan were
obtained and alpha-fetoprotein levels were assessed to rule
out focal malignant liver lesions.
Patients received thymosin alpha 1 in a dose of 1.6
mg by subcutaneous injection twice a week and interferon
alfa 2b in a dose of 3 million units by subcutaneous injec-
tion 3 times a week. Ribavirin was given in a dose of
800mg/day for patients weighing <60 kg, 1000mg for
patients between 60-70 kg and 1200 mg for patients with
>70 kg body weight. Patients were followed up in the clin-
ic at weeks 2 and 4 and then at monthly intervals until the
end of treatment. The following evaluations were performed
at each visit: physical examination, assessment of any
adverse event, concomitant medications, and assessment of
compliance, hematology and biochemistry. Determination
of serum HCV RNA was performed at months one, three,
six and nine; at the end of treatment and at six months post
treatment. 
Patients who completed six months of treatment
were evaluated for response to therapy which was defined
as negativity of serum HCV RNA by PCR. Patients who
were considered as responders continued the treatment till
the end of 52 weeks. These patients were seen at 3 months
and 6 months after the end of treatment to evaluate for the
sustained response.
Results
Eleven patients were included in the study, eight
female and three males, with a median age was 42 years
(range 28-50). The liver biopsy showed grade 0-1 necro-
inflammatory activity in 4 and grade 3 in 7 patients. The
stage of the disease was 0-2 in 7, and 3-4 in 4 patients. HCV
genotype was type 1 in five, and 3 in six patients.
Baseline median ALT was 76 IU/L (range 33 - 198)
and HCV RNA was 3.17 million units per milliliter (range
0.15-10.16). There were six patients in this study who were
non-responders to the previous interferon plus ribarivin
therapy while five patients had relapsed after a successful
end of treatment response. Two groups differed in the base-
line HCV RNA which was much higher in non-responders
(5.59±3.29x106 IU/ml) as compared to relapsers (1.15
±1.83x106 IU/ml) (p=0.022) (Table).
Non-responders to the combination of interferon
plus ribavirin therapy remained non-responders to the triple
regimen of thymosin with interferon and ribavirin after six
months of therapy, though improvement in ALT levels was
observed during the treatment. However, one patient had a
Figure. Response to the triple therapy: ALT and HCV RNA levels in “relapsers” and “non-respon-
ders” to interferon plus ribavirin therapy.
significant drop of HCV RNA levels. His genotype
was 1 and baseline HCV RNA 8.43x106 IU/ml, which
decreased to 0.63x106 IU/ml at month six. This was consid-
ered to be an interim response and therapy was continued.
This patient was still positive by reverse transcriptase PCR
at month twelve when treatment was stopped and he was
initially considered to be a therapeutic failure. However,
HCV RNA became negative at six months and remained
negative at twelve months post-treatment and he was con-
sidered to have a successful sustained response in the final
analysis. The relapsers to the combination therapy showed
response to triple regimen. Four out of five patients (geno-
type 1=2, genotype 3=2) became negative after six months
of therapy and continued their treatment.  Their end of treat-
ment HCV RNA was negative and all showed sustained
virological response measured at six months post treatment.
Minor adverse effects were observed during treatment with
this combination therapy and these included myalgia (4), a
mild form of alopecia (4), local discomfort at the injection
sites (3) and weight loss (1). No serious adverse events were
reported.
Discussion
Thymosin alpha 1 is an immune modulator that has
been shown to increase the production of Th1 cytokines
such as IL-2 in peripheral blood mononuclear cells from
patients infected with HCV. Smaller increases are also seen
after treatment with IFN-alpha, while thymosin alpha 1 and
IFN-alpha together have a synergistic effect. Thymosin
alpha 1 has also been shown to decrease the Th2 cytokines
IL-4 and IL-10, whereas IFN-alpha increased these
cytokines. Interestingly, a Th2 response is suggested to be
associated with persistence of HCV infection.11 Hence, thy-
mosin treatment could benefit patients with hepatitis C
infection by increasing the Th1 response, important for sus-
tained clearance of hepatitis C; and by decreasing the Th2-
type response, associated with persistence of viremia. 
Thymosin alpha 1 may not be effective as a
monotherapy in the treatment of chronic hepatitis C.12
However, its combination with interferon effectively
improves the response rate. In one randomized, double-
blinded, placebo-controlled trial, end-of-treatment bio-
chemical response was seen in 37.1% of patients treated
with combination therapy of interferon and thymosin,
16.2% of patients treated with IFN alone, and 2.7% of
untreated controls.  Cumulative sustained biochemical
responses were 14.2% and 8.1% in the IFN/TA1 and IFN
arms respectively, based on an intention-to-treat model.13 In
another study using thymosin and lymphoblastoid interfer-
on, sustained virological response of 40% was seen, includ-
ing a sustained response of 39% in patients infected with
HCV genotype 1.14 Ongoing studies of combination of thy-
mosin with pegylated interferon are expected to show fur-
ther improvement in the sustained response rate. 
In our study we included difficult to treat patients.
These were the patients who had not responded to the pre-
vious treatment or had relapsed in the follow up period.
There is still no satisfactory treatment available for these
patients. In the present study, retreatment with the triple reg-
imen was, as expected, more beneficial in relapsers than in
non-responders. In addition, thymosin alpha 1 did not add
toxicities to those already expected from either interferon
alpha with or without ribavirin. Taken together, these data
suggest that the addition of thymosin alpha 1 to interferon
and ribavirin is beneficial to patients who relapsed after the
end of therapy for chronic hepatitis C. 
Table. Characteristics and response to the triple regimen in relapsers
and non-responders to the previous interferon plus ribavirin treatment.
Non-responders Relapsers P value
(n = 6) (n = 5)
Sex (M/F) 2/4 1/4
Age (yrs.) Mean +S.D. 44.0+8.0 39.6+7.6
HCV genotype
1 3 3
3 3 3
Liver biopsy (grade)
0-1 2 2
2-3 4 3
Stage 0-2 4 3
3-4 2 2
Baseline HCV RNA 5.59+3.29 1.15+1.82 0.022
(x106 IU/ml) 
mean + S.D.)
Baseline ALT (IU/L) 74.33+23.7 102.2+80.5 0.436
(mean + S.D.)
HCV RNA at month 6.69+5.67 0.32+0.65 0.035
six (x106 IU/ml)
(mean + S.D.)
ALT (IU/L) at month 40.8+16.9 20.8+6.7 0.035
six (mean + S.D.)
End of treatment 0/6 4/5 0/015
virological response
Sustained virological 1/6* 4/5 0.080
response
p values by two sided Fisher exact test and independent sample t-test.
*One patient was HCV RNA positive at the end of treatment but became
negative at six months and twelve months post-treatment.
How to deal with the initial non-responders is still an
unresolved dilemma. Our patients of this group did show an
initial decline in the HCV RNA level. However, all of them
were non-responders at month six based on the stopping
rule set for this trial. Therefore, treatment was stopped in all
except one who had shown significant decrease in HCV
RNA level and became PCR negative after stopping treat-
ment at month 12. This late clearance of the virus is not seen
with standard therapy and may be related to sustained stim-
ulation of the immunological mechanism eventually clear-
ing the virus. A delayed response to thymosin alpha 1 has
been consistently demonstrated in patients with chronic
hepatitis B.15 It is possible that similar immune mecha-
nisms, perhaps related to Th1 stimulation, are involved in
response to thymosin alpha 1 therapy in HCV infection as
well. Until more is known about the incidence of delayed,
sustained response in HCV infection, we suggest that in-
treatment virological response should not be used to deter-
mine whether or not to interrupt therapy that includes thy-
mosin alpha 1. 
Thymosin alpha 1 is an expensive drug. The cost of
triple therapy especially in relation to those who have
already received interferon and ribavirin is an important
issue for patients living in a third world country. The cost
would further increase if pegylated interferon replaces ordi-
nary interferon in such triple regimens. However, not many
options are available for difficult to treat patients. In sum-
mary, our data suggest that thymosin alpha 1 may be a use-
ful addition to the treatment of relapsers and non-respon-
ders, and further studies are warranted.
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